Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TSHA
stocks logo

TSHA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.38M
-22.76%
-0.098
+39.56%
1.89M
-6.58%
-0.103
+29.16%
1.20M
-47.87%
-0.107
+18.52%
Estimates Revision
The market is revising Downward the revenue expectations for Taysha Gene Therapies, Inc. (TSHA) for FY2025, with the revenue forecasts being adjusted by -14.41% over the past three months. During the same period, the stock price has changed by 50.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-14.41%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.27%
In Past 3 Month
Stock Price
Go Up
up Image
+50.60%
In Past 3 Month
Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.060
sliders
Low
5.00
Averages
10.50
High
14.00
Current: 5.060
sliders
Low
5.00
Averages
10.50
High
14.00
Goldman Sachs
Salveen Richter
Early-Stage Biotech -> Buy
upgrade
$11
2025-12-04
New
Reason
Goldman Sachs
Salveen Richter
Price Target
$11
2025-12-04
New
upgrade
Early-Stage Biotech -> Buy
Reason
Goldman Sachs analyst Salveen Richter moved its rating on Taysha Gene Therapies to Buy with an $11 price target from Early-Stage Biotech designation. The firm is positive on the company's outlook in Rett syndrome. believe Taysha can achieve the response rate of 33% needed to meet the minimum threshold for success in the REVEAL study, the analyst tells investors in a research note.
Cantor Fitzgerald
Kristen Kluska
upgrade
$13 -> $19
2025-11-21
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$13 -> $19
2025-11-21
upgrade
Reason
Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Taysha Gene Therapies to $19 from $13 and keeps an Overweight rating on the shares.
Citizens JMP
Outperform
maintain
$6 -> $8
2025-11-05
Reason
Citizens JMP
Price Target
$6 -> $8
2025-11-05
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Taysha Gene Therapies to $8 from $6 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported Q3 results and provided a safety update on 12 dosed patients and a finalized statistical analysis plan that is achievable based on available data, the analyst tells investors in a research note. Finalized REVEAL plans have weathered the regulatory storm, and Citizens believes the protocol is currently the best approach in Rett, giving Taysha a significant competitive advantage.
Raymond James
Strong Buy
initiated
$13
2025-10-20
Reason
Raymond James
Price Target
$13
2025-10-20
initiated
Strong Buy
Reason
Raymond James initiated coverage of Taysha Gene Therapies with a Strong Buy rating and $13 price target. Based on "strong results" from Part A of the Phase 1/2 REVEAL trial and "constructive" feedback from FDA, the firm views Taysha as well-positioned for success in its pivotal trial for patients with Rett syndrome, the analyst tells investors. There are currently no approved therapies addressing the root genetic cause of Rett syndrome, which the firm sees giving Taysha "a clear path to success," the analyst added.
Canaccord
Buy
maintain
$11 -> $14
2025-08-13
Reason
Canaccord
Price Target
$11 -> $14
2025-08-13
maintain
Buy
Reason
Canaccord raised the firm's price target on Taysha Gene Therapies to $14 from $11 and keeps a Buy rating on the shares. The firm said its 2Q25 report was largely uneventful as TSHA-102's pivotal REVEAL Part B study remains on track with site activations already in progress and patient enrollment expected to commence in 4Q25. They also note the company is now capitalized through Ph3 data following its May financing.
Chardan
Buy
maintain
$9 -> $10
2025-08-12
Reason
Chardan
Price Target
$9 -> $10
2025-08-12
maintain
Buy
Reason
Chardan raised the firm's price target on Taysha Gene Therapies to $10 from $9 and keeps a Buy rating on the shares. The company reported that it has commenced site activation activities for the pivotal Part B REVEAL trial of TSHA-102 for Rett syndrome, and expects to report additional supplemental data from Part A of the trial in Q4, the analyst tells investors in a research note. The company also expects its cash position to support a runway into 2028 vs. into Q4 from February 2025 guidance, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Taysha Gene Therapies Inc (TSHA.O) is -12.16, compared to its 5-year average forward P/E of -4.36. For a more detailed relative valuation and DCF analysis to assess Taysha Gene Therapies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.36
Current PE
-12.16
Overvalued PE
-1.67
Undervalued PE
-7.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.45
Undervalued EV/EBITDA
-5.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
40.20
Current PS
0.00
Overvalued PS
92.08
Undervalued PS
-11.67
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 124.21% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 649.63% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 124.21% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TSHA News & Events

Events Timeline

(ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
select
link
2025-11-04 (ET)
2025-11-04
07:07:35
Taysha Gene Therapies projects funding to last until 2028.
select
2025-11-04
07:07:07
Taysha Gene Therapies Announces Q3 EPS of 9c, Matching Consensus Estimates
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
12-04SeekingAlpha
Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment

  • Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.

  • Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.

  • Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.

  • Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.

[object Object]
Preview
5.0
12-02Yahoo Finance
Insider at Taysha Gene Therapies Sells Shares Valued at $1,695,906, Recent SEC Filing Reveals

  • Leadership Role: Sukumar Nagendran serves as the Director, President, and Head of Research & Development.

  • Date of Announcement: The information was shared on November 28, 2025.

[object Object]
Preview
8.0
11-11NASDAQ.COM
"Invest in Taysha Gene Therapies at $2.50 and Achieve 24% Returns with Options"

  • Put Selling and Upside Potential: Selling a put option on Taysha Gene Therapies Inc does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which depends on the stock price falling significantly.

  • Counterparty Risk and Myths: The article discusses common myths about options, including counterparty risk, emphasizing that the put seller's only benefit is the premium collected unless the stock price drops enough to warrant exercising the option.

  • Volatility and Trading History: The historical volatility of Taysha Gene Therapies Inc is noted to be 98%, which, along with the stock's trading history, can help assess the risk-reward balance of selling the December 2026 put option at a $2.50 strike price.

  • Investment Considerations: Investors are encouraged to analyze both the stock's historical performance and fundamental factors when considering the potential return of 21.8% annualized from selling the put option.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Taysha Gene Therapies Inc (TSHA) stock price today?

The current price of TSHA is 5.06 USD — it has increased 12.69 % in the last trading day.

arrow icon

What is Taysha Gene Therapies Inc (TSHA)'s business?

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

arrow icon

What is the price predicton of TSHA Stock?

Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Taysha Gene Therapies Inc (TSHA)'s revenue for the last quarter?

Taysha Gene Therapies Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Taysha Gene Therapies Inc (TSHA)'s earnings per share (EPS) for the last quarter?

Taysha Gene Therapies Inc. EPS for the last quarter amounts to -0.09 USD, decreased -10.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Taysha Gene Therapies Inc (TSHA)'s fundamentals?

The market is revising Downward the revenue expectations for Taysha Gene Therapies, Inc. (TSHA) for FY2025, with the revenue forecasts being adjusted by -14.41% over the past three months. During the same period, the stock price has changed by 50.60%.
arrow icon

How many employees does Taysha Gene Therapies Inc (TSHA). have?

Taysha Gene Therapies Inc (TSHA) has 73 emplpoyees as of December 05 2025.

arrow icon

What is Taysha Gene Therapies Inc (TSHA) market cap?

Today TSHA has the market capitalization of 1.39B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free